{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:47:01Z","timestamp":1789055221903,"version":"build-2803163510"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-111-PP-28"],"award-info":[{"award-number":["CA-111-PP-28"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2321-B-037-002"],"award-info":[{"award-number":["MOST 111-2321-B-037-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-KI110001"],"award-info":[{"award-number":["KMU-KI110001"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.esmoop.2022.100746","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T17:48:17Z","timestamp":1671126497000},"page":"100746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan"],"prefix":"10.1016","volume":"8","author":[{"given":"Y.-Y.","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.-J.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.-N.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-Y.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-5189","authenticated-orcid":false,"given":"Y.-S.","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7167","authenticated-orcid":false,"given":"L.-T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100746_bib1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100746_bib2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00280-014-2671-x","article-title":"Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients","volume":"75","author":"Chang","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2022.100746_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1186\/s12885-016-2933-6","article-title":"A\u00a0phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors","volume":"16","author":"Chiang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2022.100746_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.esmoop.2022.100746_bib5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6602042","article-title":"UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer","volume":"91","author":"Marcuello","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100746_bib6","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"10.1016\/j.esmoop.2022.100746_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s100380050100","article-title":"Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese","volume":"44","author":"Akaba","year":"1999","journal-title":"J\u00a0Hum Genet"},{"key":"10.1016\/j.esmoop.2022.100746_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00280-010-1485-8","article-title":"UGT1A1\u22171\/\u221728 and \u22171\/\u22176 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer","volume":"68","author":"Sunakawa","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.esmoop.2022.100746_bib9","first-page":"801","article-title":"Linkage disequilibrium of UGT1A1 \u22176 and UGT1A1 \u221728 in relation to UGT1A6 and UGT1A7 polymorphisms","volume":"16","author":"Urawa","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.esmoop.2022.100746_bib10","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/jco.2006.24.18_suppl.2063","article-title":"Distribution of UGT1A1 (TA) polymorphisms in Caucasian and Asian subjects","volume":"24","author":"Liu","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100746_bib11","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","article-title":"Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin","volume":"24","author":"Han","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100746_bib12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1124\/dmd.104.001800","article-title":"Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American","volume":"33","author":"Kaniwa","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.esmoop.2022.100746_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cpt.720","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer","volume":"102","author":"Adiwijaya","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2022.100746_bib14","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/psp4.12725","article-title":"Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer","volume":"10","author":"Brendel","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.esmoop.2022.100746_bib15","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/annonc\/mdt002","article-title":"A\u00a0randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"24","author":"Roy","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100746_bib16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/bjc.2013.408","article-title":"A\u00a0multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer","volume":"109","author":"Ko","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2022.100746_bib17","doi-asserted-by":"crossref","first-page":"9396","DOI":"10.1002\/cam4.3558","article-title":"nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients","volume":"9","author":"Ueno","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2022.100746_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/cas.14264","article-title":"Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study","volume":"111","author":"Bang","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2022.100746_bib20","article-title":"Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: a real-world multicenter study","volume":"12","author":"Su","year":"2022","journal-title":"Front Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922003805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:29:15Z","timestamp":1761856155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922003805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2059702922003805"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100746","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100746"}}